Sentinel Lymph Node Biopsy in Melanoma Patients: The Medical Oncologist's Perspective

Paola Queirolo, Paola Taveggia, Marco Gipponi, Mario Roberto Sertoli

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

With the advent of sentinel node (sN) biopsy in melanoma patients, elective lymph node dissection (ELND) can be considered an exceeded procedure. Regardless of the possible therapeutic benefits, sN biopsy efficiently predicts prognosis avoiding the morbidity rate of ELND. The importance of the sN is underlined by multivariate analyses, which show that the sN status represents the most important prognostic factor influencing disease-free and distant disease-free survival in patients with stage I and II melanoma. Moreover, sN biopsy provides a minimally invasive method for identifying those patients with subclinical nodal metastasis who actually have stage III disease, with a very high risk of occult distant metastases and who may benefit by adjuvant therapy.

Original languageEnglish
Pages (from-to)162-165
Number of pages4
JournalJournal of Surgical Oncology
Volume85
Issue number3
DOIs
Publication statusPublished - Mar 1 2004

Fingerprint

Sentinel Lymph Node Biopsy
Melanoma
Lymph Node Excision
Biopsy
Neoplasm Metastasis
Disease-Free Survival
Multivariate Analysis
cyhalothrin
Oncologists
Morbidity
Therapeutics

Keywords

  • Adjuvant treatment
  • Cutaneous melanoma
  • Sentinel lymph node

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Sentinel Lymph Node Biopsy in Melanoma Patients : The Medical Oncologist's Perspective. / Queirolo, Paola; Taveggia, Paola; Gipponi, Marco; Sertoli, Mario Roberto.

In: Journal of Surgical Oncology, Vol. 85, No. 3, 01.03.2004, p. 162-165.

Research output: Contribution to journalArticle

Queirolo, Paola ; Taveggia, Paola ; Gipponi, Marco ; Sertoli, Mario Roberto. / Sentinel Lymph Node Biopsy in Melanoma Patients : The Medical Oncologist's Perspective. In: Journal of Surgical Oncology. 2004 ; Vol. 85, No. 3. pp. 162-165.
@article{00f916fa26194a1e8c245b0dafefbea6,
title = "Sentinel Lymph Node Biopsy in Melanoma Patients: The Medical Oncologist's Perspective",
abstract = "With the advent of sentinel node (sN) biopsy in melanoma patients, elective lymph node dissection (ELND) can be considered an exceeded procedure. Regardless of the possible therapeutic benefits, sN biopsy efficiently predicts prognosis avoiding the morbidity rate of ELND. The importance of the sN is underlined by multivariate analyses, which show that the sN status represents the most important prognostic factor influencing disease-free and distant disease-free survival in patients with stage I and II melanoma. Moreover, sN biopsy provides a minimally invasive method for identifying those patients with subclinical nodal metastasis who actually have stage III disease, with a very high risk of occult distant metastases and who may benefit by adjuvant therapy.",
keywords = "Adjuvant treatment, Cutaneous melanoma, Sentinel lymph node",
author = "Paola Queirolo and Paola Taveggia and Marco Gipponi and Sertoli, {Mario Roberto}",
year = "2004",
month = "3",
day = "1",
doi = "10.1002/jso.20029",
language = "English",
volume = "85",
pages = "162--165",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Sentinel Lymph Node Biopsy in Melanoma Patients

T2 - The Medical Oncologist's Perspective

AU - Queirolo, Paola

AU - Taveggia, Paola

AU - Gipponi, Marco

AU - Sertoli, Mario Roberto

PY - 2004/3/1

Y1 - 2004/3/1

N2 - With the advent of sentinel node (sN) biopsy in melanoma patients, elective lymph node dissection (ELND) can be considered an exceeded procedure. Regardless of the possible therapeutic benefits, sN biopsy efficiently predicts prognosis avoiding the morbidity rate of ELND. The importance of the sN is underlined by multivariate analyses, which show that the sN status represents the most important prognostic factor influencing disease-free and distant disease-free survival in patients with stage I and II melanoma. Moreover, sN biopsy provides a minimally invasive method for identifying those patients with subclinical nodal metastasis who actually have stage III disease, with a very high risk of occult distant metastases and who may benefit by adjuvant therapy.

AB - With the advent of sentinel node (sN) biopsy in melanoma patients, elective lymph node dissection (ELND) can be considered an exceeded procedure. Regardless of the possible therapeutic benefits, sN biopsy efficiently predicts prognosis avoiding the morbidity rate of ELND. The importance of the sN is underlined by multivariate analyses, which show that the sN status represents the most important prognostic factor influencing disease-free and distant disease-free survival in patients with stage I and II melanoma. Moreover, sN biopsy provides a minimally invasive method for identifying those patients with subclinical nodal metastasis who actually have stage III disease, with a very high risk of occult distant metastases and who may benefit by adjuvant therapy.

KW - Adjuvant treatment

KW - Cutaneous melanoma

KW - Sentinel lymph node

UR - http://www.scopus.com/inward/record.url?scp=1542288894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542288894&partnerID=8YFLogxK

U2 - 10.1002/jso.20029

DO - 10.1002/jso.20029

M3 - Article

C2 - 14991888

AN - SCOPUS:1542288894

VL - 85

SP - 162

EP - 165

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -